

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	tba	Art Unit:	tba
Filed:	tba	Examiner:	tba
1 <sup>st</sup> Inventor:	Tomomi IKEMOTO	Allowed:	
For:	Process for the Preparation of 2, 3-Dihydroazepine Compounds	Batch:	
Atty. Dkt. No.	2645 USOP	Paper No.:	

Information Disclosure Statement

BOX Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

Sir:


Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference is herewith being provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: March 4, 2001

(847) 383-3372  
(847) 383-3391

  
Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

Page 1 of 1							
FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) <i>(Use several sheets if necessary)</i> Date Submitted to PTO:	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; padding: 5px;">ATTY DOCKET NO.: 2645 USOP</td> <td style="width: 70%; padding: 5px;">           SERIAL NO.:  <div style="font-size: 2em; font-weight: bold; text-align: center;">10/070329</div>           tba         </td> </tr> </table>	ATTY DOCKET NO.: 2645 USOP	SERIAL NO.: <div style="font-size: 2em; font-weight: bold; text-align: center;">10/070329</div> tba				
ATTY DOCKET NO.: 2645 USOP	SERIAL NO.: <div style="font-size: 2em; font-weight: bold; text-align: center;">10/070329</div> tba						
APPLICANT: IKEMOTO, T.							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; padding: 5px;">FILING DATE: tba</td> <td style="width: 70%; padding: 5px;">           GROUP: tba            Examiner tba         </td> </tr> </table>		FILING DATE: tba	GROUP: tba Examiner tba				
FILING DATE: tba	GROUP: tba Examiner tba						
<b>U.S. PATENT DOCUMENTS</b>							
<b>*EXAMINER INITIAL</b>	<b>REF No.</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE IF APPROPRIATE</b>
	A1	3,632,636	1/4/1972	Wei, et al.	260	517	
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>*EXAMINER INITIAL</b>	<b>REF No.</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION YES NO</b>
	A2	WO 99/32100	7/1/1999	WIPO			
	A3	WO99/32468	7/1/1999	WIPO			
	A4	EP 0138492	4/24/1985	EP			
	A5	EP 0237918	9/23/19887	EP			
	A6	EP 0126294	11/28/1984	EP			
<b>OTHER DOCUMENT(S)</b>							
<b>*EXAMINER INITIAL</b>	<b>REF No.</b>	<b>AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.</b>					
	A7	Appollina, et al. "Synthesis and renal vasodilator activity of substituted [4-alkyl(aryl)quinazolin-2-one-1-yl]alkanoic acids" EUR J. MED. CHEM 27:277-284 (1992)					
<b>EXAMINER:</b>				<b>DATE CONSIDERED:</b>			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.